133 related articles for article (PubMed ID: 8454912)
1. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
2. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
3. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
[TBL] [Abstract][Full Text] [Related]
5. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Musolino C; Grosso P; Alonci A; Allegra A; Orlando A; Cincotta M; Buda G; Squadrito G
Am J Hematol; 1993 May; 43(1):1-4. PubMed ID: 8317456
[TBL] [Abstract][Full Text] [Related]
7. 2',5'-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B.
Furuta M; Akashi K; Nakamura Y; Matsumoto K; Yamaguchi H; Takamatsu S; Shimizu T
J Interferon Res; 1987 Feb; 7(1):111-9. PubMed ID: 3585079
[TBL] [Abstract][Full Text] [Related]
8. Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.
Pawlotsky JM; Hovanessian AG; Roudot-Thoraval F; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
Antimicrob Agents Chemother; 1996 Feb; 40(2):320-4. PubMed ID: 8834873
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
[TBL] [Abstract][Full Text] [Related]
10. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
Millar BC; Bell JB
Br J Cancer; 1995 Dec; 72(6):1525-30. PubMed ID: 8519671
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis.
Kakumu S; Arao M; Yoshioka K; Ichimiya H; Murase K; Aoi T; Kusakabe A
Am J Gastroenterol; 1989 Jan; 84(1):40-5. PubMed ID: 2521421
[TBL] [Abstract][Full Text] [Related]
12. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
13. Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Apr; 26(2):162-9. PubMed ID: 1710193
[TBL] [Abstract][Full Text] [Related]
14. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
[TBL] [Abstract][Full Text] [Related]
16. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
Rosenblum MG; Maxwell BL; Talpaz M; Kelleher PJ; McCredie KB; Gutterman JU
Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
[TBL] [Abstract][Full Text] [Related]
17. Interferon-induced 2'-5' oligoadenylate synthetase during interferon-alpha therapy in homosexual men with Kaposi's sarcoma: marked deficiency in biochemical response to interferon in patients with acquired immunodeficiency syndrome.
Preble OT; Rook AH; Steis R; Silverman RH; Krause D; Quinnan GV; Masur H; Jacob J; Longo D; Gelmann EP
J Infect Dis; 1985 Sep; 152(3):457-65. PubMed ID: 2993441
[TBL] [Abstract][Full Text] [Related]
18. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
19. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.
Lam NP; Pitrak D; Speralakis R; Lau AH; Wiley TE; Layden TJ
Dig Dis Sci; 1997 Jan; 42(1):178-85. PubMed ID: 9009135
[TBL] [Abstract][Full Text] [Related]
20. Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C.
Pawlotsky JM; Hovanessian A; Roudot-Thoraval F; Lebon P; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
J Interferon Cytokine Res; 1995 Oct; 15(10):857-62. PubMed ID: 8564707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
